

(19)



Europäisches Patentamt

European Patent Office

Office européen des brevets



(11)

EP 0 593 868 B1

SN 09/317,688 (B6)

(12)

EUROPEAN PATENT SPECIFICATION

(45) Date of publication and mention
of the grant of the patent:
15.04.1998 Bulletin 1998/16

(51) Int Cl.⁶: C07K 14/56, A61K 47/48,
C08G 65/32, C07D 213/64,
C07C 69/96

(21) Application number: 93112983.7

(22) Date of filing: 13.08.1993

(54) **PEG-interferon conjugates**

PEG-Interferon-Konjugate

Conjugués PEG-interféron

(84) Designated Contracting States:
AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL
PT SE

- Nalin, Carlo
Franklin Lakes, N.J. 07417 (US)
- Rosen, Perry
North Caldwell, N.J. 07006 (US)

(30) Priority: 26.08.1992 US 935770

(43) Date of publication of application:
27.04.1994 Bulletin 1994/17

(74) Representative: Mezger, Wolfgang, Dr. et al
F.Hoffmann-La Roche AG
Patent Department (PLP),
124 Grenzacherstrasse
4070 Basel (CH)

(73) Proprietor: F. HOFFMANN-LA ROCHE AG
4002 Basel (CH)

(72) Inventors:
• Karasiewicz, Robert
Parsippany, N.J. 07054 (US)

(56) References cited:
EP-A- 0 154 316 EP-A- 0 400 472
EP-A- 0 426 488 EP-A- 0 510 356
WO-A-87/00056

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

Description

Various natural and recombinant proteins have medical and pharmaceutical utility. Once they have been purified and formulated, they can be parenterally administered for various therapeutic indications. However, parenterally administered proteins may be immunogenic, may be relatively water insoluble, and may have a short pharmacological half life. Consequently, it can be difficult to achieve therapeutically useful blood levels of the proteins in patients.


These problems may be overcome by conjugating the proteins to polymers such as polyethylene glycol. Davis et al., U.S. Pat. No. 4,179,337, disclose conjugating polyethylene glycol (PEG) to proteins, such as enzymes and insulin, in order to result in conjugates where the protein would be less immunogenic but would retain a substantial proportion of its physiological activity. Nakagawa, et al. (U.S. Pat. No. 4,791,192) disclose conjugating PEG to islet-activating protein to reduce its side-effects and immunogenicity. Veronese et al., *Applied Biochem. and Biotech.*, **11**:141-152 (1985), disclose activating polyethylene glycols with phenyl chloroformates to modify a ribonuclease and a superoxide dismutase. Katre et al., U.S., Pat. Nos. 4,766,106 and 4,917,888, also disclose solubilizing proteins by polymer conjugation. PEG and other polymers are conjugated with recombinant proteins to reduce their immunogenicity and increase their half-life. See Nitecki, et al., U.S. Pat. No. 4,902,502, Enzon, Inc., International Application Publ. No. WO 90/13540. Nishimura et al., European Patent Application 154,316 and Tomasi, International Application Pub. No. WO 86/04145.

EP 426,488 describes the coupling of a PEG/PPG polymer to superoxide dismutase wherein the resulting compound has the formula



Previous methods of forming PEG/protein conjugates and the conjugates which result from said methods present several problems. Among these problems is that certain methods of forming these protein-PEG conjugated may inactivate the protein so that the resulting conjugates may have poor biological activity. In addition, certain linkers utilized in forming these PEG-protein conjugates may be susceptible to *in vivo* hydrolytic cleavage. When such cleavage occurs after administration, these conjugates lose the beneficial properties provided by PEG.

One embodiment of the invention are novel interferon-PEG conjugates with unique linkers which connect an interferon (IFN) amino group to PEG. The present invention is directed in particular to physiologically active interferon conjugates having the general formula:



wherein R is C1-C4 alkyl; R¹, R², R³ and R⁴ are H or C1-C4 alkyl;

m is 1 or 2;



W is O or NH;

x is an integer between 1 and 1000 and each of y and z is an integer from 0 to 1000, and the sum of x, y and z is 3 to 1000;

with the proviso that at least one of R¹, R², R³ and R⁴ is C1-C4 alkyl and x, y, z are selected such that the molecular weight of the polymeric unit in the conjugate is in the range of about 1000 daltons to about 10000 daltons.

It is self-evident that the -NH-group in formula I is derived from an accessible amino group of the interferon molecule.

More specifically the two different interferon conjugates have the following formulae:



wherein R is C1-C4 alkyl; R¹, R², R³, R⁴ are H or C1-C4 alkyl; m 1 or 2; x, y, z are as under formula I above; with the proviso mentioned under formula I above.


Brief Description of the Figures

Figure 1: Time course of PEG modification with the compound of Example 7. Interferon (5 mg/ml) was incubated with 10-fold, 20-fold, or 40-fold excess of reagent to protein for the times indicated in 25 mM Tricine (pH 10.0), 0.5 M KSCN, 100 mM NaCl. Aliquots were removed at various times, quenched with glycine and analyzed on a 15% SDS-PAGE gel. On the label "I" is for interferon.

Figure 2: Time course of PEG modification with the compound of Example 5. Interferon was incubated with a 3-fold or 10-fold excess of reagent for the indicated times as in Figure 1. At the times indicated, aliquots were removed, quenched with glycine, and analyzed on a 15% SDS-PAGE gel. "S" is the label for protein molecular weight standards, "I" is the label for interferon.

Figure 3: Comparison of PEG modification with the compound of Example 1 (left side), and of Example 3 (right side). Interferon was incubated with a 3-fold excess of each reagent for 0.25, 1.5 or 24 hours. Aliquots were removed, quenched with glycine and analyzed on a 15% SDS-PAGE gel. "S" is the label for protein molecular weight standards, "I" is the label for interferon.

In accordance with this invention, the IFN conjugates of formulae IA and IB can be produced by condensing activated PEG where a terminal hydroxy or amino group has been replaced by an activated linker. These reagents can then react with one or more of the amino groups in the IFN. Condensation with only one amino group to form a monoPEGylated conjugate is a preferred embodiment of this invention. Therefore, the invention also relates to novel activated compounds (reagents) which can be used to produce the interferon conjugates of the present invention. These compounds have the following general formulae:




wherein R is C1-C4 alkyl, R¹, R², R³, and R⁴ are H or C1-C4 alkyl provided that at least one of R¹, R², R³ and R⁴ is C1-C4 alkyl;

R⁵ is H or C1-C4 alkyl when W is NH or R⁵ is H when W is O; W is NH or O;

x is an integer between 1 and 1000 and each of y and z is an integer from 0 to 1000, and the sum of x, y and z is 3 to 1000 and x, y and z are selected such that the molecular weight of the polymeric unit in the conjugate is in the range of about 1000 daltons to about 10000 daltons.



and



wherein R is C1-C4 alkyl; R¹, R², R³ and R⁴ are H or C1-C4 alkyl, x is an integer from 1 to 1000 and each of y and z is an integer from 0 to 1000, and the sum of x, y and z is 3 to 1000,

wherein at least one of R¹, R², R³ and R⁴ is C1-C4 alkyl and wherein x, y and z are selected such that the molecular weight of said compound is in the range of about 1000 daltons to about 10000 daltons.

More specifically, formula II includes compounds of the following two types:



In IIA and IIB R, R¹, R², R³, R⁴, R⁵ and x, y, and z and the proviso are as above.

In accordance with this invention, by using the activated PEG reagents of formula IIA, IIB, or III to produce the conjugates, a linking bond between the free amino groups in a protein such as interferon (IFN) and the PEG is formed so that the resulting conjugate retains at least a portion of the biological activity of the protein with reduced immunogenicity. In addition, the linkage groups formed in the conjugate of this invention through the use of any one of the activated polyethylene glycols of formulae IIA, IIB, or III produces a protein conjugate which is not readily susceptible to *in vivo* hydrolytic cleavage and is not subject to the disadvantages present in PEG protein conjugates of the prior art.

In accordance with this invention, R, R¹, R², R³, R⁴, and R⁵ can be any lower alkyl, preferably methyl. The term lower alkyl designates lower alkyl groups containing from 1 through 6 carbon atoms, such as methyl, ethyl, n-propyl, isopropyl, etc. Generally the preferred alkyl group is a lower alkyl group containing from 1 to 4 carbon atoms with methyl

being most preferable. R_1 , R_2 , R_3 , R_4 , and R_5 can also be hydrogen, but R^1 , R^2 , R^3 and R_4 are not simultaneously hydrogen.

In accordance with this invention, x, y, and z can be selected from any combination of numbers such that the resulting conjugate contains at least a portion of the biological activity of the IFN which forms the conjugate. It is apparent that the sum of x, y, and z, and m is inversely proportional to the amount of biological activity of the IFN which is retained by the conjugate. The numerical value of x, y, and z represent the number of glycol units in the polyglycol which form the conjugate. The term m represents the number of free or accessible amino groups contained by the IFN which can react with the activated PEG mixture. The higher the value of m, and x, y, and z, the higher the molecular weight of the conjugate. In accordance with this invention x, y and z are any number so that molecular weight of the conjugate, excluding the weight of the protein, is between about 300 to about 30,000 daltons. Preferably for IFN, m is a number from 1 through 3. A highly preferred embodiment is a monoPEGylated conjugate where m is 1, produced by conditions such that a high yield is obtained of IFN conjugate composed of IFN where only one free amino group has reacted with the PEG reagent of formula II-A, or II-B, or III. In accordance with a preferred embodiment where m is 1, x, y, and z are any number so that the glycol which forms the conjugate has an average molecular weight of from about 300 to about 30,000 daltons, preferably about 1,000 to about 10,000 daltons, especially about 1,000 to about 5,000 daltons. In a particularly preferred embodiment, the molecular weight is about 2,000 daltons.

As far as the numbers x, y and z of the units are concerned, x is an integer from 1 to 1000 and each of y and z is an integer from 0 to 1000 and the sum of x, y and z is 3 to 1000.

In one preferred embodiment of the conjugates of formulae IA and IB, x and y are 5 to 500 and z is 0 to 4. In a particularly preferred embodiment, the glycol used is a mixture of glycols wherein x is between 10 to 100, y is between 1 to 10 and z is 0. Most preferred is an interferon conjugate of formula IA wherein m is 1, R , R^2 and R^4 are CH_3 ; R^1 is H; x is about 19, y is about 2 and z is 0. This corresponds to an average molecular weight in the PEG unit of about 1000 daltons.

In order to avoid any doubts concerning the numbers of the units in the PEG molecule, characterization of the polyethylene glycol polymer by molecular weight is preferred over indicating the number of self repeating units (SRU) in the PEG polymer by x, y and z. These values may be difficult to assess due to potential inhomogeneity of the starting PEG compounds which are usually defined by their average molecular weight and not by the number of self-repeating units they contain. The starting PEG compounds of various molecular weights can be prepared by methods known in the art or can be obtained from commercial suppliers.

In case the values of x, y and z obtained by determination of the molecular weights or as indicated by the supplier are not integers (as will generally be the case), their values have to be rounded up or off in the usual way to allow an assignment of the integers to the polymeric molecule which probably forms the major part in the polymeric mixture.

When the reagent of any one of formula II-A, II-B, or III is reacted with an IFN, which contains more than one free amino group, the conjugate may be produced as a mixture of various reaction products of IFN with the PEG-reagent mixtures. These reaction products form as a result of the reaction of the PEG reagent with one or more of the free amino groups. This is sided by m in formula IA and IB. For example, where the IFN contains three free amino groups, the activated PEG reagent can react with one of the free amino groups, with two of the free amino groups or with all three. In this situation the mixture contains conjugated reaction products formed in all three cases. Since the various conjugated reaction products in this mixture have vastly different molecular weights, depending on the value of m, i.e. 1, 2, or 3, these reaction products can be separated by conventional methods such as chromatography. To determine if m, and x, y, and z have been selected properly, the separated conjugated reaction products can be screened for biological activity by the same means used to screen the parent IFN to determine if the conjugated reaction product still retains a portion of the biological activity of the IFN used to form the conjugate. In this manner, the numbers m, and x, y, and z can be adjusted in any desired manner to provide the desired activity.

In accordance with the preferred embodiment, m is 1. Where m is 1, this conjugate can be obtained even when there are two or more free amino groups. The activated PEG reagent will react first with one of the free amino groups contained within the IFN. By regulating the concentration of the reagents such as the IFN, and reaction conditions, in accordance with standard methods of amine condensation, one can regulate the degree of pegylation of the free amino groups contained within the protein. In proteins containing one or more free amino groups, where one of the free amino groups is more reactive than the other amino groups, conditions may be selected so that the protein is reacted with the activated PEG compound to form the compound of formula IA or IB where m is 1. Other free amino groups contained within amino acids which form the protein may be subsequently reacted with the PEG by allowing the condensation reaction to proceed longer or by utilizing other stronger conditions.

As used in the present specification and claims the terms interferon and IFN include all types of interferon (viz. molecules with an interferon activity), for example, α , β , γ and ω interferon, and all subtypes of these types, such as $\alpha 1$, $\alpha 2$, $\alpha 2A$, $\alpha 2B$ or $\alpha 2C$ and hybrids or chimeras of different types and/or subtypes. The interferon can be of whatever origin and may be obtained from natural sources, tissue cultures or by recombinant DNA techniques. Methods for producing and isolating natural or recombinant interferons are well known in the art and are described, e.g. in patent

applications, Publ. Nos. EP 43 980, EP 211 148, EP 140 127, DE 3 028 919, USP 4 503 035 and USP 4 414 150.


The advantage of using the reagents of formulae IIA, IIB and III where at least one of R^1 , R^2 , R^3 , R^4 is lower alkyl, in particular methyl (alkyl substituted reagents) lies in an unexpected enhancement of the yield of conjugate, i.e., PEGylated protein, when the alkyl substituted reagents are used as compared to corresponding unsubstituted reagents.

Alkyl substituted reagents yield at least twice the amount of conjugates in the same amount of reaction time compared to the corresponding unsubstituted reagents in producing such conjugates.

If administered to patients for therapeutic purposes, the conjugates of formulae IA and IB produced from the above-described substituted reagents would have an unexpectedly enhanced *in vivo* half-life in the bloodstream of the patient when compared to conjugate formed from corresponding unsubstituted reagents. Although *in vivo* half-life is directly proportional to the molecular weight of the conjugate, a conjugate produced from a substituted reagent, surprisingly will have as long a half-life as a higher molecular weight conjugate produced from unsubstituted reagent. A longer half-life for a therapeutic agent in a patient's bloodstream provides enhanced efficiency for administering the agent to a patient. For example, conjugates made from alkyl substituted reagents can be administered less frequently and/or in lower amounts than conjugates made from the corresponding unsubstituted reagent. In order to enhance the efficiency of administration of biologically active protein conjugates with polyethylene glycol, increased molecular weights of polyethylene glycol have been used in forming these protein conjugates. However, biological efficacy of the active conjugated IFN diminishes with increasing molecular weight. However, through the use of the conjugates of this invention produced with substituted reagents, efficiency of administration is enhanced over the use of the corresponding unsubstituted conjugate with less increase in molecular weight.


In another embodiment, the present invention also relates to processes for the preparation of the novel conjugates.

The conjugate of formula I-A can be produced as follows:




PEG-amine

IV



IIA


NH₂-protein

I-A

wherein R, R¹, R², R³, R⁴, and R⁵, m and x, y, and z are as above; with the proviso that any one or more of R¹, R², R³, R⁴ may be lower alkyl.

In this reaction a PEG-amine is mixed with the compound of formula IV in a hydrocarbon or chlorinated hydrocarbon solvent to produce the compound of formula IIA. The compound of formula IIA can be condensed in an aqueous medium with one or more of the free amino groups of the protein to produce the conjugate of formula IA. This reaction can be carried out under conventional conditions for condensing amines in an aqueous medium. Generally this reaction is carried out in a standard aqueous buffer solution having a pH of between 7 and 10 to produce the conjugate of formula IA. This reaction may produce a mixture of PEG protein conjugates of various molecular weights depending upon the number of free amino groups within the protein and the time of the reaction. The PEG protein conjugates may then be separated into their individual components by conventional methods such as high performance liquid chromatography (HPLC) or gel electrophoresis. Any conventional conditions for separating compounds by molecular weight with HPLC or gel electrophoresis may be used. Separation of this mixture can be carried out according to molecular weights of the products formed as described herein.

An IFN conjugate of formula IB can be prepared according to the following reaction scheme:




wherein R, R¹, R², R³, R⁴, R⁵, m, x, y, z and the proviso are as above.

The compound of formula IV is produced by condensing phosgene with 2-hydroxypyridine (substituted if R⁵ = lower alkyl) using any conventional method for condensing an acid halide with an alcohol.

The condensation of a PEG alcohol with the compound of formula IV is effected by using conventional conditions for condensing an alcohol with a carbonate to produce the compound of formula II-B. The compound of formula II-B is condensed with the protein through one or more free amino groups on the protein to produce the compound of formula I-B. This reaction is carried out in the manner described for the condensation of the compound of formula IIA to produce the conjugate of formula I-A. Depending upon the number of free amino groups contained within the protein which react with the compound of formula II-B, the conjugate of formula I-B may be formed as a mixture of conjugates having different molecular weights. This conjugate mixture can be separated in the manner described hereinbefore.

The compound of formula IB can also be produced using the following reaction scheme:



wherein R, R¹, R², R³, R⁴, R⁵, m, x, and y are as above.

In this reaction scheme, PEG-alcohol is condensed with the compound of formula IV to produce the compound of formula III. In this reaction, the compound of IIB is formed as an intermediate which then reacts with a second mole of PEG-alcohol to produce the compound of formula III. In carrying out this reaction, the PEG-alcohol is present in at least 2 moles per mole of the compound of formula IV. In this procedure any conventional method of condensing an alcohol with a carbonate can be used. The compound of formula III is reacted with interferon to form the conjugate of formula I-B in the manner described for the conversion of the compound of formula IIA to the compound of formula IA. Depending upon the amount of free amino groups contained by the protein, condensation of the compound of formula III with the protein produces a mixture of conjugates which can be separated into their individual components in the manner hereinbefore described for the separation of the conjugate of formula IA.

In accordance with this invention, it has been found that the interferon-conjugates of this invention have the same utility as the protein used to form the conjugate. Therefore, these conjugates are therapeutically active in the same manner as the protein from which they are formed and can be used in the same manner as the protein itself without producing the undesired immune responses which may be connected with the administration to subjects of the proteins themselves. Therefore, the present invention also comprises the pharmaceutical compositions on the basis of the compounds of formula I or their salts and to methods for producing them.

The pharmaceutical compositions of the present invention used in the control or prevention of illnesses comprises an interferon conjugate of the general formula I and a therapeutically inert, non toxic and therapeutically acceptable carrier material. The pharmaceutical compositions to be used can be formulated and dosed in a fashion consistent with good medical practice taking into consideration the disorder to be treated, the condition of the individual patient, the site of delivery of the protein conjugate, the method of administration and other factors known to practitioners.

The following examples represent illustrative embodiments of the present invention without limiting it by them.

As used in these examples, Jeffamine M-2070 is a 2070 average molecular weight monomethoxypolyoxyalkylene propylamine polymer derived from propylene and ethylene oxide which is composed of a polyethylene glycol backbone and contains an average of 30% randomly incorporated propylene oxide groups.

Jeffamine M-1000 is a 1000 average molecular weight monomethoxypolyalkylene propylamine polymer derived from propylene and ethylene oxide which is composed of a polyethylene glycol backbone containing 14% of specifically incorporated propylene oxide groups where x is an average of 18.6, y is an average of 1.6, and z is 0 (x, y and z are used here with the same significance as described above).

All reagents described in these examples may be stored dessicated in amber glass at 4°C until needed. Fresh aliquots are used for each modification.

Examples

Reference Example 1

Preparation of alpha, alpha-Oxomethylene bis[omega-methoxypoly(oxy-1,2-ethanediyl)]SRU 111

From a suspension of 1.5 g MPEG (methoxypolyethylene glycol) (m.w. -5000) in 80 ml of dry toluene was distilled 50 ml of solvent. The solution was then cooled and 30.5 mg of di-2-pyridylcarbonate added. The resulting mixture was then refluxed for 24 hr. The solution was then cooled and the resulting precipitate filtered and washed with a small volume of toluene followed by diethyl ether. The solid was then dried under high vacuum to give 0.6 g of alpha, alpha'-oxomethylene bis(omega-methoxypoly(oxy-1,2-ethanediyl)) SRU 111 as a white powder. PEG-modified interferon was prepared by method 1 described below.

Preparation of PEG-modified Interferon-alpha.

Method 1: Recombinant interferon-alpha at 5 mg protein per ml was dialyzed against a buffer containing 5 mM sodium acetate, pH 5.0, 120 mM NaCl. Potassium thiocyanate was added to obtain a final concentration of 0.5 M, and the pH adjusted by addition of one-tenth volume of 1 M Tricinesodium hydroxide, pH 11.9, to obtain a final pH 10.0 solution. PEG-reagent was added to the protein at a 3:1 molar ratio from solid or dissolved in DMSO (the volume of DMSO was less than 10% of the total). Modification was allowed to proceed at room temperature for a time from 30 minutes to 4 hours, followed by addition of 1 M L-glycine (pH 6.3) to a final concentration of 20 mM to stop further modification. PEG-modified protein was precipitated by addition of 3.5 M ammonium sulfate, 50 mM sodium phosphate, pH 7.0, to a final concentration of 1.1 M ammonium sulfate (1.0 M ammonium sulfate for a PEG-10000), the precipitate collected by centrifugation, washed and redissolved in 25 mM ammonium acetate, pH 5.0. PEG-modified proteins were purified by chromatography on a hydrophobic exchange column (for example 75 x 7.5 mm) such as BioRad TSK Phenyl-5-PW or Toyopearl Phenyl-650M, using a gradient of decreasing ammonium sulfate in 50 mM sodium phosphate, pH 7.0. Alternatively, PEG-IFN was purified by gel filtration on a

Sephacryl S-200 column (for example a 90 cm. x 3.2 cm. column) (Pharmacia) that was equilibrated in 25 mM sodium acetate (pH 5.0), 200 mM NaCl. PEG-modified protein was identified by SDS-PAGE. Protein eluted from the column corresponding to interferon having one (PEG₁-IFN) or two (PEG₂-IFN) bound PEG were pooled, concentrated and protein determined by absorbance at 280 nm or by colorimetric assay (Pierce). PEG-IFN was stored at 4°C in buffer containing 50 mM sodium phosphate, pH 7.0, 0.3 M ammonium sulfate.

Method 2: Interferon α -2a at a protein concentration of approximately 6 mg per mL, was dialyzed into 5 mM sodium acetate, pH 5.0, 0.12 M sodium chloride. The protein concentration was determined by measuring the absorbance at 280 nm using 1.0 mg⁻¹mL as the extinction coefficient. The protein solution was mixed with the modifying reagent at a 1:3 molar ratio of protein to reagent. The modification reaction was initiated by adjusting the pH to 10.0 using one-tenth volume of 0.1 M Na₂B₄O₇-NaOH, pH 10.7. Following incubation at room temperature for one hour, the reaction was stopped by addition of one-twentieth volume of 1 M glycine, pH 7.5. After 3-5 minutes, the pH was decreased to 5.0-6.0 by addition of one-twentieth volume of 1 M sodium acetate, pH 4.0.

The solution containing PEG-interferon, quenched reagent and unmodified interferon was diluted four-fold with 40 mM ammonium acetate, pH 4.5, and loaded onto a CM-cellulose column (Whatman CM-52, approximately 0.5 ml resin per mg protein). After washing the column by 5 volumes of 40 mM ammonium acetate, pH 4.5, PEG-interferon and unmodified interferon were eluted using a linear sodium chloride gradient (0 - 0.5 M) in the 40 mM ammonium acetate pH 4.5. Fractions containing protein were identified by absorbance at 280 nm, and PEG-interferon containing fractions were identified by SDS-PAGE.

PEG-interferon was further purified by size exclusion-gel filtration chromatography on a column containing Sephacryl S-200 resin (Pharmacia LKB). Fractions eluted from the column were analyzed by SDS-PAGE and the peak material containing PEG-interferon pooled.

Reference Example 2

Preparation of alpha, alpha-Oxomethylene bis[omega-methoxypoly(oxy-1,2-ethanediyl)]SRU 28.3

By the procedure described in Example 1, MPEG (m.w. 1300) was converted to alpha, alpha-oxomethylene bis[omega-methoxypoly(oxy-1,2-ethanediyl)] SRU 28.3, and PEG-modified interferon was prepared using this reagent by method 1 described in Example 1.

Reference Example 3

Preparation of alpha-Methyl-omega-[2[(2-Pyridinyloxy)carbonyl]oxy]-ethoxy]-poly-(oxy-1,2-ethanediyl) SRU 111.7

From a solution of 1 g MPEG molecular weight 5000 dissolved in 30 ml of dry CH₂Cl₂ was distilled 10 ml of solvent. The solution was cooled to room temperature and 132 mg (0.6 mM) of di-2-pyridyl carbonate and 4 mg of DMAP were added. The resulting solution was then stirred for 14 hours and the solvent removed under vacuum. The residue was triturated with diethyl ether and the resulting precipitate filtered. The product was then dissolved in 7 ml of dry glyme, warmed to cause dissolution, and the resulting solution allowed to cool and stand at room temperature for several hours. The resulting precipitate was then filtered and washed with 2x5 ml of dry glyme. The solid was then dried in a vacuum oven and under a stream of nitrogen to give 0.7 g of alpha-[(2-pyridinyloxy)carbonyl]omega-methoxypoly(oxy-1,2-ethanediyl) SRU 111.7.

Anal. Calcd for C₉H₁₁NO₄(CH₂CH₂O)_{111.7}: C, 54.57; H, 9.02; N, 0.28. Found: C, 54.51; H, 9.19; N, 0.28.

PEG-modified interferon was prepared using this reagent by method 1 described in Example 1.

Reference Example 4

Preparation of alpha-(2-Pyridinyloxy)carbonyl]omega-methoxypoly(oxy-1,2-ethanediyl) SRU 225

By the procedure described in Example 3, MPEG molecular weight 10,000 was converted to alpha-[(2-pyridinyloxy)carbonyl]omega-methoxypoly(oxy-1,2-ethanediyl), SRU 225.


Anal. Calcd for C₉H₁₁NO₄(CH₂CH₂O)₂₂₅: C, 54.54; H, 9.08; N, 0.14. Found: C, 54.54; H, 9.12; N, 0.11.

PEG-modified interferon was prepared using this reagent by method 1 described in Example 1.

Example 5Preparation of alpha-Methyl-omega-[2-[2-[(2-pyridinyloxy) carbonyl]oxy]-propoxy]propoxy]poly(oxy-1,2-ethanediyl) SRU 64.7

From a solution of 0.5 g of alpha-2-[2-(hydroxypropoxy)propyl]-omega-methoxypoly(oxy-1,2-ethanediyl) SRU 64.7 in 40 ml of dry CH_2Cl_2 was distilled 15 ml of solvent. To the solution was then added 108 mg of di-2-pyridyl carbonate, 4 mg of DMAP and several beads of 4A molecular sieve. The mixture was then stirred overnight, filtered and the solvent was then removed under reduced pressure. The residue was purified by means of size exclusion chromatography.

This reagent corresponds to a compound with the formula



wherein n is about 64.

This corresponds to a molecular weight in the polymer of about 3000 daltons.

PEG-modified interferon was prepared using this reagent by method 1 described in Example 1.

Example 6Preparation of alpha-Methyl-omega-[2-[2-[(2-pyridinyloxy)carbonyl]oxy]-propoxy]propoxy]poly(oxy-1,2-ethanediyl)SRU 110

By the procedure described in Example 5, alpha-2-[2-(hydroxypropoxy)propyl]-omega-methoxypoly(oxy-1,2-ethanediyl) SRU 110, was converted to alpha-methyl-omega-[2-[2-[(2-pyridinyloxy)carbonyl]oxy]-propoxy]propoxy]poly(oxy-1,2-ethanediyl) SRU 110.


This reagent (IIB-2) corresponds to the one described in Example 5 (IIB-1) except that n is about 110 which corresponds to about 5000 daltons.

PEG-modified interferon was prepared using this reagent by method 1 described in Example 1.

Example 7Preparation of Methylloxirane, polymer with oxirane, [2[[2-(2-pyridinyloxy)-carbonyl]amino]propyl]methyl ether (MO/O = 10/32)

From a solution of 1 g of Jeffamine M-2070 (Texaco Chemical Co.) in 40 ml of dry CH_2Cl_2 was distilled 15 ml of solvent. The solution was cooled to 0°C and 215 mg of di-2-pyridyl carbonate was added. The resulting solution was stirred for an additional 4 hr at 0°C after which time the solvent was removed under reduced pressure. The residue was then purified by means of two phenomenex size exclusion columns attached in sequence (500Å and 1000 Å). The product shows two bands in the UV at 232 nm and 310 nm.

This reagent corresponds to a compound with the formula



wherein R^5 is H, R^2 is H or methyl, and, as an average distribution, n is 32 if R^2 is H and n is 10 if R^2 is methyl. PEG-modified interferon was prepared using this reagent by method 2 described in Example 1.

Example 8Preparation of Methyloxirane, polymer with oxirane, [2-[[[3-methyl-2-pyridinyloxy)carbonyl]amino]propyl methyl ether (MO/O = 10/32)

By the procedure described in Example 7, 1 g of Jeffamine M-2070 was reacted with bis(3-methyl-2-pyridyl)carbonate to give methyloxirane, polymer with oxirane, [2-[[[3-methyl-2-pyridinyloxy)carbonyl]amino]propyl methyl ether (MO/O = 10/32).


This reagent (IIA-2) corresponds to the one described in Example 7 (IIA-1) except that R⁵ is CH₃.

PEG-modified interferon was prepared using this reagent by method 1 described in Example 1.

Example 9Preparation of Methyloxirane, polymer with oxirane, [2-[[[2-pyridinyloxy)-carbonyl]amino]propyl methyl ether, block (MO/O = 1.6/18.6)

By the procedure described in Example 7, 0.6 g of Jeffamine M-1000 (Texaco Chemical Co.) was reacted with 155.6 mg of di-2-pyridyl carbonate to give methyloxirane, polymer with oxirane, [2-[[[2-pyridinyloxy)carbonyl]-amino]propyl methyl ether, block (MO/O = 1.6/18.6).

This yields a compound with the formula



having the indicated average distribution of the units in the polymeric product.

PEG-modified interferon was prepared using this reagent by method 1 described in Example 1.

Antiviral activity of Interferon: Antiviral activity of interferon and PEG-modified interferon was determined (Rubenstein, et al., (1981) J. Virol. 37:755-758; Familletti, et al., (1981) Methods Enzymol. 78:387-394). All assays were standardized relative to control. The interferon standard used in the assay had specific activity of 2×10^8 units per mg of protein.

Conditions used for modification of interferon were based on optimized protocols as described. PEG-modification was analyzed by SDS-PAGE for conversion of interferon to monoPEG-interferon over various times of incubation (chemical reactivity), and for distribution into different species of PEG-interferon conjugates (site selectivity). In SDS-PAGE, PEG-modified species were observed as slower migrating bands on the gel. Both monoPEG and diPEG-interferons were produced in sufficient yield so that these species could be purified from the reaction mixtures by hydrophobic interaction chromatography. Purified PEG-interferons were tested for antiviral activity and compared with unmodified interferon-a2a standards. The molecular weights of the polymers used as well as the antiviral activity of some of the pegylated derivatives are described in Table 1.

Table 1


Physical Properties of PEG Reagents and Biological Activities of their Protein Conjugates			
Compound of Example:	Polymer Mol/Wt.	Antiviral Activity (% control)	
		monoPEG	diPEG
4	10000	25	2
3	5000	40	4
1	5000	40	ND
6	5000	40	ND
5	3000	60	ND
7	2070	45	ND

Table 1 (continued)

Physical Properties of PEG Reagents and Biological Activities of their Protein Conjugates			
Compound of Example:	Polymer Mol/Wt.	Antiviral Activity (% control)	
		monoPEG	diPEG
2	1300	70	ND
9	1000	100	40
ND = not determined			

Claims

1. An interferon conjugate of the formula:



wherein R is C1-C4 alkyl; R¹, R², R³ and R⁴ are H or C1-C4 alkyl;


m is 1 or 2;

W is O or NH;

x is an integer between 1 and 1000 and each of y and z is an integer from 0 to 1000, and the sum of x, y and z is 3 to 1000;

with the proviso that at least one of R¹, R², R³ and R⁴ is C1-C4 alkyl. and x, y and z are selected such that the molecular weight of the polymeric unit in the conjugate is in the range of about 1000 daltons to about 10 000 daltons.

2. An interferon conjugate of claim 1 wherein m is 1.
3. An interferon conjugate of claim 1 wherein R is methyl.
4. An interferon conjugate of claim 1 wherein x, y and z are selected such that the molecular weight of the polymeric unit in the conjugate is in the range of about 1000 daltons to about 5000 daltons.
5. An interferon conjugate of claim 1 wherein x, y and z are selected such that the molecular weight of the polymeric unit in the conjugate is in the range of about 1000-2200 daltons.
6. An interferon conjugate of claim 1 wherein x and y are 5.0 to 500.0 and z is 0.0 to 4.0.
7. An interferon conjugate of claim 1 wherein x is 10.0 to 100.0, y is 1.0 to 10.0 and z is 0.
8. An interferon conjugate of claim 1 wherein the interferon is interferon α2A.
9. The interferon conjugate of claim 8 wherein W is NH; m is 1; R, R² and R⁴ are CH₃; R¹ is H; x is 18.6, y is 1.6 and z is 0.
10. A compound of formula:



wherein R is C1-C4 alkyl; R¹, R², R³, R⁴ are H or C1-C4 alkyl provided that at least one of R¹, R², R³ and R⁴ is C1-C4 alkyl; R⁵ is H or C1-C4 alkyl when W is NH or R⁵ is H when W is O;


W is NH or O;

x is an integer between 1 and 1000 and each of y and z is an integer from 0 to 1000, and the sum of x, y and z is 3 to 1000 and x, y and z are selected such that the molecular weight of the polymeric unit in the conjugate is in the range of about 1000 daltons to about 10 000 daltons,

11. A compound of claim 10 wherein R is methyl.

12. A compound of claim 10 wherein x is 10.0 to 100.0, y is 1.0 to 10.0 and z is 0.0 to 4.0.

13. A compound of the formula:



wherein R is C1-C4 alkyl; R¹, R², R³, and R⁴ are H or C1-C4 alkyl, x is an integer from 1 to 1000 and each of y and z is an integer from 0 to 1000, and the sum of x, y and z is 3 to 1000, wherein at least one of R¹, R², R³ and R⁴ is C1-C4 alkyl, and wherein x, y and z are selected such that the molecular weight of said compound is in the range of about 1000 daltons to about 10 000 daltons.

14. A compound of claim 13 wherein R is methyl.

15. Interferon conjugates in accordance with any one of claims 1-9 for use as therapeutically active compounds in the treatment or prophylaxis of illnesses.

16. Process for the preparation of an interferon conjugate as claimed in any one of claims 1-9, which process comprises reacting a compound claimed in claims 10-14 with interferon or a salt thereof and isolating the interferon conjugate from the reaction mixture.


17. Pharmaceutical compositions comprising an interferon conjugate as claimed in any one of claims 1-9 and a therapeutically inert carrier.

18. Pharmaceutical compositions for the treatment or prophylaxis of immunomodulatory disorders such as neoplastic diseases or infectious diseases comprising an interferon conjugate as claimed in any one of claims 1-9 and a therapeutically inert carrier.

19. The use of interferon conjugates according to any one of claims 1-10 for the manufacture of medicaments for use in the treatment or prophylaxis of illnesses.

Patentansprüche

1. Interferon-Konjugat der Formel:



worin R C1-C4-Alkyl ist; R¹, R², R³ und R⁴ H oder C1-C4-Alkyl sind;

m 1 oder 2 ist;

W O oder NH ist;

x eine ganze Zahl zwischen 1 und 1000 ist und jede von y und z eine ganze Zahl von 0 bis 1000 ist und die Summe von x, y und z 3 bis 1000 ist;

mit der Maßgabe, daß mindestens einer von R¹, R², R³ und R⁴ C1-C4-Alkyl ist und x, y und z so gewählt sind, daß das Molekulargewicht der Polymereinheit in dem Konjugat im Bereich von etwa 1000 Dalton bis etwa 10 000 Dalton ist.

2. Interferon-Konjugat nach Anspruch 1, worin m 1 ist.

3. Interferon-Konjugat nach Anspruch 1, worin R Methyl ist.

4. Interferon-Konjugat nach Anspruch 1, worin x, y und z so gewählt sind, daß das Molekulargewicht der Polymereinheit in dem Konjugat im Bereich von etwa 1000 Dalton bis etwa 5000 Dalton ist.

5. Interferon-Konjugat nach Anspruch 1, worin x, y und z so gewählt sind, daß das Molekulargewicht der Polymereinheit in dem Konjugat im Bereich von etwa 1000-2200 Dalton ist.


6. Interferon-Konjugat nach Anspruch 1, worin x und y 5,0 bis 500,0 sind und z 0,0 bis 4,0 ist.

7. Interferon-Konjugat nach Anspruch 1, worin x 10,0 bis 100,0 ist, y 1,0 bis 10,0 ist und z 0 ist.

8. Interferon-Konjugat nach Anspruch 1, worin das Interferon Interferon-α2A ist.

9. Interferon-Konjugat nach Anspruch 8, worin W NH ist; m 1 ist; R, R² und R⁴ CH₃ sind; R¹ H ist; x 18,6 ist, y 1,6 ist und z 0 ist.

10. Verbindung der Formel:



worin R C1-C4-Alkyl ist, R¹, R², R³, R⁴ H oder C1-C4-Alkyl sind, vorausgesetzt, daß mindestens einer von

R^1 , R^2 , R^3 und R^4 C1-C4-Alkyl ist; R^5 H oder C1-C4-Alkyl ist, wenn W NH ist, oder R^5 H ist, wenn W O ist;


W NH oder O ist;

x eine ganze Zahl zwischen 1 und 1000 ist und jede von y und z eine ganze Zahl von 0 bis 1000 ist und die Summe von x, y und z 3 bis 1000 ist und x, y und z so gewählt sind, daß das Molekulargewicht der Polymer-einheit in dem Konjugat im Bereich von etwa 1000 Dalton bis etwa 10 000 Dalton ist.

11. Verbindung nach Anspruch 10, worin R Methyl ist.

12. Verbindung nach Anspruch 10, worin x 10,0 bis 100,0 ist, y 1,0 bis 10,0 ist und z 0,0 bis 4,0 ist.

13. Verbindung der Formel:



worin R C1-C4-Alkyl ist; R^1 , R^2 , R^3 und R^4 H oder C1-C4-Alkyl sind, x eine ganze Zahl von 1 bis 1000 ist und jede von y und z eine ganze Zahl von 0 bis 1000 ist und die Summe von x, y und z 3 bis 1000 ist, worin mindestens einer von R^1 , R^2 , R^3 und R^4 C1-C4-Alkyl ist und worin x, y und z so gewählt sind, daß das Molekulargewicht der Verbindung im Bereich von etwa 1000 Dalton bis etwa 10 000 Dalton ist.

14. Verbindung nach Anspruch 13, worin R Methyl ist.

15. Interferon-Konjugate nach einem der Ansprüche 1-9 zur Verwendung als therapeutisch wirksame Verbindungen bei der Behandlung oder Prophylaxe von Erkrankungen.

16. Verfahren zur Herstellung eines Interferon-Konjugats, wie in einem der Ansprüche 1-9 beansprucht, wobei das Verfahren die Umsetzung einer in den Ansprüchen 10-14 beanspruchten Verbindung mit Interferon oder einem Salz davon und die Isolierung des Interferon-Konjugats aus der Reaktionsmischung umfaßt.


17. Pharmazeutische Zusammensetzungen, umfassend ein Interferon-Konjugat, wie in einem der Ansprüche 1-9 beansprucht, und einen therapeutisch inerten Träger.

18. Pharmazeutische Zusammensetzungen zur Behandlung oder Prophylaxe immunmodulatorischer Erkrankungen wie neoplastischen Krankheiten oder infektiösen Krankheiten, umfassend ein Interferon-Konjugat, wie in einem der Ansprüche 1-9 beansprucht, und einen therapeutisch inerten Träger.

19. Verwendung von Interferon-Konjugaten nach einem der Ansprüche 1-10 zur Herstellung von Medikamenten zur Verwendung bei der Behandlung oder Prophylaxe von Erkrankungen.

Revendications

1. Conjugué d'interféron de formule :



10 dans laquelle R est un groupe alkyle en C₁-C₄; R¹, R², R³ et R⁴ sont H ou des groupes alkyle en C₁-C₄;

m vaut 1 ou 2 :

West O ou NH :

x est un entier compris entre 1 et 1000, et chacun des indices y et z est un entier allant de 0 à 1000, et la somme de x, y et z est de 3 à 1000 :

à la condition qu'au moins l'un des radicaux R¹, R², R³ et R⁴ soit un groupe alkyle en C₁-C₄.

et x, y et z sont choisis de façon que la masse moléculaire du motif polymère du conjugué soit comprise dans l'intervalle d'environ 1000 daltons à environ 10 000 daltons.

20 2. Conjugué d'interféron selon la revendication 1, dans lequel m vaut 1.

3. Conjugué d'interféron selon la revendication 1, dans lequel R est le groupe méthyle.

25 4. Conjugué d'interféron selon la revendication 1, dans lequel x, y et z sont choisis de façon que la masse moléculaire du motif polymère du conjugué soit comprise entre environ 1000 daltons et environ 5000 daltons.

5. Conjugué d'interféron selon la revendication 1, dans lequel x, y et z sont choisis de façon que la masse moléculaire du motif polymère du conjugué soit comprise entre environ 1000 et 2200 daltons.


30 6. Conjugué d'interféron selon la revendication 1, dans lequel x et y valent de 5,0 à 500,0, et z vaut de 0,0 à 4,0.

7. Conjugué d'interféron selon la revendication 1, dans lequel x vaut de 10,0 à 100,0, y vaut de 1,0 à 10,0, et z vaut 0.

8. Conjugué d'interféron selon la revendication 1, dans lequel l'interféron est l'interféron $\alpha 2A$.

9. Conjugué d'interféron selon la revendication 8, dans lequel W est NH ; m vaut 1, R, R² et R⁴ représentent CH₃ ; R¹ est H ; x vaut 18.6, y vaut 1.6 et z vaut 0.

10. Composé de formule :




dans laquelle R est un groupe alkyle en C₁-C₄, R¹, R², R³, R⁴ sont chacun H ou un groupe alkyle en C₁-C₄, à la condition qu'au moins l'un des radicaux R¹, R², R³ et R⁴ soit un groupe alkyle en C₁-C₄; que R⁵ soit H ou un groupe alkyle en C₁-C₄ quand W est NH, ou que R⁵ soit H quand W est O;

West NH ou O :

x est un entier compris entre 1 et 1000, et chacun des indices y et z est un entier de 0 à 1000, et la somme de x, y et z est de 3 à 1000, et x, y et z sont choisis de façon que la masse moléculaire du motif polymère du conjugué soit comprise entre environ 1000 et environ 10 000 daltons.

11. Composé selon la revendication 10, dans lequel R est le groupe méthyle.
12. Composé selon la revendication 10, dans lequel x vaut de 10,0 à 100,0, y vaut de 1,0 à 10,0 et z vaut de 0,0 à 4,0.
13. Composé de formule :



dans lequel R est un groupe alkyle en C₁-C₄, R¹, R², R³ et R⁴ sont chacun H ou un groupe alkyle en C₁-C₄, x est un entier de 1 à 1000, et chacun des indices y et z est un entier de 0 à 1000, et la somme de x, y et z est de 3 à 1000, où au moins l'une des radicaux R¹, R², R³ et R⁴ est un groupe alkyle en C₁-C₄, et où x, y et z sont choisis de façon que la masse moléculaire dudit composé soit comprise entre environ 1000 daltons et environ 10 000 daltons.

14. Composé selon la revendication 13, dans lequel R est le groupe méthyle.
15. Conjugués d'interféron selon l'une quelconque des revendications 1 à 9, pour utilisation en tant que composés thérapeutiquement actifs dans le traitement ou la prophylaxie de maladies.
16. Procédé pour préparer un conjugué d'interféron selon l'une quelconque des revendications 1 à 9, lequel procédé consiste à faire réagir un composé selon les revendications 10 à 14 avec un interféron ou un sel de ce dernier, et à isoler le conjugué d'interféron d'avec le mélange réactionnel.
17. Compositions pharmaceutiques comprenant un conjugué d'interféron selon l'une quelconque des revendications 1-9 et un excipient inerte d'un point de vue thérapeutique.
18. Compositions pharmaceutiques pour le traitement ou la prophylaxie de troubles de l'immunomodulation tels que les maladies néoplasiques ou les maladies infectieuses, comprenant un conjugué d'interféron selon l'une quelconque des revendications 1 à 9 et un excipient inerte d'un point de vue thérapeutique.
19. Utilisation de conjugués d'interféron selon l'une quelconque des revendications 1-10, pour la préparation de médicaments destinés à être utilisés dans le traitement ou la prophylaxie de maladies.

FIGURE 1




FIGURE 2





FIGURE 3



**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.